1 / 57

Nasopharyngeal Carcinoma

Nasopharyngeal Carcinoma. พ.ท. ขจรเกียรติ ประสิทธิเวชชากูร. Epidermiology. Incidence. Rare neoplasm in most parts of world Higher incidence in Chinease & Taiwan Chinease gene increase incidence of NPC Age > 40 years . Incidence.

jud
Download Presentation

Nasopharyngeal Carcinoma

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript


  1. Nasopharyngeal Carcinoma พ.ท. ขจรเกียรติ ประสิทธิเวชชากูร

  2. Epidermiology

  3. Incidence • Rare neoplasm in most parts of world • Higher incidence in Chinease & Taiwan • Chinease gene increase incidence of NPC • Age > 40 years

  4. Incidence • Emigration fromhigh incidence to low incidence area reduces incidence of NPC • Male : female = 3:1

  5. Risk factor • Genetic maker of NPC  HLA-A2( found in Chineasepopulation ) • EB-virus • Nitrosamines • Polycyclic hydrocarbons • Chronic nasal sinus infection • Poor hygiene

  6. Anatomy

  7. Pathology

  8. Pathology • The most common is squamous cell carcinoma • Most common position is Rosenmuller fossa • Mass lesion • exophytic mass • Ulcerative mass • Infiltrative mass

  9. Histopathology

  10. Histopathology • Base on predominant histologic type • WHO type 1 : Squamous cell carcinoma nonkeratizing • WHO type 2 : Trasitional cell carcinoma

  11. Histopathology • WHO type 3 : Undifferentiated carcimomas • Lymphoepitheliomas • Anaplastic carcinomas

  12. WHO type 1 • Squamous cell carcinoma nonkeratizing • Strong intracellular bridges • Less keratin production • Less associate EBV • 25% of case • Radioresistant tumor

  13. WHO type 2 • Trasitional cell carcinoma • Not produce keratin • Greater degree of tumor pleomorphism • Most common is papillary morphology • 12% of case

  14. WHO type 3 • Undifferentiated carcimomas • Lymphoepitheliomas, Anaplastic carcinomas, Clear cell carcinoma, Spindle cell carcinoma • Most common cell type of NPC • Clear nucleus • 63% aggressive behavior • Radiosensitive

  15. Tumor Spreading

  16. Local invasion • Anterior : involve hard palate, medial pterygoid plate, ethmoid & maxillary sinus • Lateral : involve internal jugular V, internal carotid A, CN IX X XI XII,

  17. Local invasion • Medial : Eustachian tube involvement, mastoid air cell • Superior : involve base of skull, throught foramen lacerum & cavernous sinus • Inferior : oropharynx & soft palate

  18. Lymphatic spreading • Most common is neck node spreading • Bilateral involvement • Most common position is upper jugular node • Least at submandibular & submental node

  19. Distance metastasis • Most common is • Bone • Lung • Liver • Other sites are rare

  20. Clinical Manifestation

  21. Clinical Manifestation • Related to location of primary tumor & course of disease • Most common complaint is Hearing loss & lump in the neck

  22. Neck mass • Most common spread to neck lymph node • Complaint neck mass • Bilateral metastasis to lymph node is common

  23. Neck mass • Most common location is Upper jugular node ( compose of jugular node, spinal accessory node ) • retropharyngeal node induce headache

  24. Frequency of lymph node manifestration • Upper jugular region • Posterior cervical group • Middle & lower jugular group • Supraclavicular group

  25. Nasal cavity involvement • Blood-tinge anterior or posteriornasal drainage • Obstruction of nasal pathway • Epistaxis • Halithosis • Nasal congest

  26. Ear involvement • Result from eustachian tubeinvolvement • Sensation of ear blockage • Serous otitis media • Conductive hearing loss • Tinitus

  27. Neurologic involvement • Cranial nerve involvement found 25 - 28% • Pain in the neck, facial pain, facial pareathesia ( CN V ) • Diplopia ( CN VI )

  28. Neurologic involvement • CN III & IV late phase • CN VII & VIII  less involvement • CN IX, X & XI  can be found

  29. Clinical Manifestation • Neck lump 60% • Ear (s) plugging & fullness 41% • Hearing loss 37% • Nasal bleeding 30% • Nasal obstruction 29% • Head pain 16% • Ear pain 14% • Neck pain 13% • Weight loss 10% • Diplopia 8% Symptom & sign of NPC frequency at diagnostic in Mayo clinic series Kuala Lumpur 1983, University of Malaya

  30. Clinical Manifestation • Neck mass 68% • Headache 58% • Ear pain 52% • Nasal obstruction, bloody discharge 48% • Facial pareathesia 22% • Dysphagia 16% • Diplopia, strabismus 14% • Facial pain, eye pain 12% • Halithosis 12% • Exopthalmos 2% Symptom from NPC found in Siriraj hospital 2532

  31. Other sign & symptom • Weight • Anorexia • low grade fever • Trismus • Nasal regurgitation of fluid

  32. Diagnostic Evaluation

  33. Clinical evaluation • History taking • Physical examination • Nasopharyngoscopy • Endoscopic nasopharyngoscopy

  34. Radiologic evaluation • Plain film head & neck • CT scan head & neck ( for evaluation & treatment planning ) • MRI ( if intracranial extension )

  35. Histopathologic evaluation • Biopsy • Most common site are roof of nasophalynx & Rosenmuller fossa

  36. Immunology • Indirect immunofluorescence for IgG & IgA antibodies to viral capsid antigen (VCA) & early antigen (EA) • Most specific test for diagnosis • Highly predictive of the clinical course • not yet commercially available

  37. Immunology • Antibody-dependent cellular cytotoxicity ( ADCC ) • Often predict the clinical course of WHO type 2&3

  38. Clinical Staging

  39. Clinical Staging • T classification • Tis carcinoma in situ • T1 tumor confine in one site of nasopharynx no tumor visible • T2 tumor involve 2 site • T3 extension of tumor into nasal cavity or oropharynx • T4 tumor invasion of skull or cranialinvolvement

  40. Clinical Staging • N Classification • Nx node cannot be assessed • N0 no regional lymph node positive • N1 single ipsilateral lymph node size< 3 cm.

  41. Clinical Staging • N2a single ipsilateral lymph node size 3 - 6 cm. • N2b multiple ipsilateral lypmh node size < 6 cm. • N2cbilateral or contralateral lymph node size < 6 cm. • N3 lymph node size > 6 cm.

  42. Clinical Staging • M classification • Mx not assessed • M0 no distance metastasis • M1 distance metastasis present

  43. Stage grouping • Stage I T1 N0 M0 • Stage II T2 N0 M0 • Stage III T3 N0 M0 T<3 N1 M0 • Stage IV T4 N<1 M0 any T N 2-3 M0 any T any N M1

  44. Treatment

More Related